XML 74 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Net revenue:        
Total net revenue [1] $ 98,826 $ 102,318 $ 188,403 $ 198,147
Cost of revenue:        
Total cost of revenue [2] 60,926 63,938 117,560 121,888
Gross profit 37,900 38,380 70,843 76,259
Operating expenses:        
Research and development 13,064 13,640 26,405 27,529
Selling and marketing 11,327 15,139 24,593 28,175
General and administrative 9,886 10,469 20,502 26,111
Total operating expenses 34,277 39,248 71,500 81,815
Income (loss) from operations 3,623 (868) (657) (5,556)
Other income (expense), net 7,766 (3,321) 3,327 (7,304)
Income (loss) before provision for income taxes 11,389 (4,189) 2,670 (12,860)
Provision for income taxes 679 451 1,316 986
Net income (loss) $ 10,710 $ (4,640) $ 1,354 $ (13,846)
Net income (loss) per share - basic $ 0.12 $ (0.05) $ 0.02 $ (0.16)
Net income (loss) per share - diluted $ 0.12 $ (0.05) $ 0.02 $ (0.16)
Weighted average common shares used in computing net loss per share:        
Basic 89,517 87,237 89,145 86,858
Diluted 90,279 87,237 90,095 86,858
Net income (loss) $ 10,710 $ (4,640) $ 1,354 $ (13,846)
Foreign currency translation adjustment 877 61 (141) (334)
Comprehensive income (loss) 11,587 (4,579) 1,213 (14,180)
Products        
Net revenue:        
Total net revenue 43,760 48,051 81,365 89,568
Cost of revenue:        
Total cost of revenue 24,518 29,062 46,088 53,586
Services        
Net revenue:        
Total net revenue 55,066 54,267 107,038 108,579
Cost of revenue:        
Total cost of revenue $ 36,408 $ 34,876 $ 71,472 $ 68,302
[1] Includes sales to the China joint venture, an equity method investment of $2,643 and $6,460 for the three and six months ended December 31, 2019 and $0 for both the three and six months ended December 31, 2018, respectively. See Note 14.
[2] Includes cost of revenue from sales to the China joint venture, an equity method investment of $2,140 and $4,631 for the three and six months ended December 31, 2019 and $0 for both the three and six months ended December 31, 2018, respectively. See Note 14.